Renal toxicity of the anticancer drug fostriecin

Cancer Chemotherapy and Pharmacology

Volumn 42, Issue 2, 1998, Pages 160-164

  De Jong, Robert S ^a   De Vries, Elisabeth G E ^a   Meijer, Sytze ^a   De Jong, Paul E ^a   Mulder, Nanno H ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Fostriecin; Nephrotoxicity; Topoisomerase II

Indexed keywords

FOSTRIECIN; IRINOTECAN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOSE RESPONSE; DRUG CLEARANCE; DRUG EFFECT; DRUG EXCRETION; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; KIDNEY TUBULE DISORDER; MALE; NEPHROTOXICITY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

ADULT; AGED; ALKENES; ANTIBIOTICS, ANTINEOPLASTIC; CREATINE; ELECTROLYTES; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; MALE; MIDDLE AGED; NEOPLASMS; PYRONES; RENAL PLASMA FLOW, EFFECTIVE; UREA;

EID: 0031805117     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050800     Document Type: Article

References (19)

1. Anthony A (1992) The biological chemistry of folate receptors. Blood 79: 2807
2. Boritzki TJ, Wolfard TS, Besserer JA, Jackson RC, Fry DW (1988) Inhibition of type II topoisomerase by fostriecin. Biochem Pharmacol 37: 4063
3. Cronin RE, Henrich WL (1996) Toxic nephropathy. In: Brenner BM (ed) Brenner and Rector's the kidney. Saunders, Philadelphia, p 1680.
4. De Jong RS, Mulder NH, Uges DRA, Graaf WTA van der, Meijer S, Vries EGE de (1996) Phase I clinical and pharmacokinetic study of 5 days 1 hour infusion of fostriecin in patients with solid tumors (abstract 351). Ann Oncol 7 [Suppl 1]: 100
5. Dimaggio JJ, Warrell RP, Muindi J, Stevens YW, Lee SJ, Lowenthal DA, Haines I, Walsh TD, Baltzer L, Yaldaei S, Young CW (1990) Phase I clinical and pharmacological study of merbarone. Cancer Res 50: 1151
6. Donker AJM, Hem GK van der, Sluiter WJ, Beekhuis HA (1977) A radioisotope method for the simultaneous determination of glomerular filtration rate (GFR) and effective renal plasma flow (ERPF). Neth J Med 20: 97
7. Fry DW, Besserer JA, Boritzki TJ (1984) Transport of the antitumor antibiotic CI-920 into L1210 leukemia cells by the reduced folate carrier system. Cancer Res 44: 3366
8. Guo XW, Thung JPH, Swank RA, Anderson HJ, Tudan C, Bradbury EM, Roberge M (1995) Chromosome condensation induced by fostriecin does not require p34(cdc2) kinase activity and histone H1 hyperphosphorylation, but is associated with enhanced histone H2A and H3 phosphorylation. EMBO J 14: 976
9. Leopold WR, Shillis JL, Mertus AE, Nelson JM, Roberts BJ, Jackson RC (1984) Anticancer activity of the structurally novel antibiotic CI-920 and its analogues. Cancer Res 44: 1928
10. Nakagawa Y, Kramer RA (1989) Nephrotoxicity of 5-(N-phenylcarboxamido)-2-thiobarbituric acid in the Fischer 344 rat. Cancer Chemother Pharmacol 25: 109
11. Nitiss JL, Beck WT (1996) Antitopoisomerase drug action and resistance. Eur J Cancer 32A: 958
12. Roberge M, Tudan C, Hung SMF, Harder KW, Jink FR, Anderson H (1994) Antitumor drug fostriecin inhibits the mitotic entry checkpoint and protein phosphatases 1 and 2A. Cancer Res 54: 6115
13. Rose BD (1989) Clinical physiology of acid-base and electrolyte disorders. McGraw-Hill, New York, p 40
14. Rowland M, Tozer TN (1995) Clinical pharmacokinetics: concepts and applications. Williams and Wilkins, Media, Pennsylvania, p 341
15. Said HM, Nguyen TT, Dyer DL, Cowan KH, Rubin SA (1996) Intestinal folate transport: identification of a cDNA involved in folate transport and the functional expression and distribution of its mRNA. Biochim Biophys Acta 1281: 164
16. 2-Microglobulin: its significance in the evaluation of renal function. Kidney Int 32: 635
17. Scheithauer W, Von Hoff DD, Clark GM, Shillis JL, Elslager EF (1986) In vitro activity of the novel antitumor antibiotic fostriecin (CI-920) in a human tumor cloning assay. Eur J Cancer Clin Oncol 22: 921
18. Stampwala SS, Bunge RH, Hurley TR (1983) Novel antitumor agents (CI-920, PD 113, 270 and PD 113, 270. II. Isolation and characterization. J Antibiot (Tokyo) 36: 1601
19. Susick RL, Hawkins KL, Pegg DG (1990) Preclinical toxicological evaluation of fostriecin, a novel anticancer antibiotic, in rats. Fundam Appl Toxicol 15: 258